Application of multimodal fusion technology in early recurrence prediction and pathological analysis of hepatocellular carcinoma

Table 2 Baseline clinical characteristics analysis

Clinical feature	Training set (n = 133)			Validation set (n = 58)
	No early recurrence (n = 77)	Early recurrence (n = 56)	P value	No early recurrence (n = 35)	Early recurrence (n = 23)	P value
Age (year)	54.49 ± 10.24	51.04 ± 10.88	0.063	50.46 ± 10.31	50.17 ± 9.73	0.917
BMI (kg/m2)	22.26 ± 3.46	22.00 ± 2.54	0.632	21.71 ± 3.41	22.80 ± 2.29	0.183
HBsAg (IU/mL)	967.49 ± 869.13	1019.11 ± 726.57	0.496	1141.26 ± 1046.98	1141.35 ± 762.88	0.893
AFP (ng/mL)	369.27 ± 494.96	539.03 ± 519.80	0.012	523.78 ± 532.39	473.20 ± 539.57	0.975
ALB (g/L)	39.35 ± 5.21	39.18 ± 4.60	0.842	41.55 ± 7.36	38.83 ± 4.59	0.069
AST (IU/L)	82.31 ± 135.98	51.94 ± 27.49	0.758	64.54 ± 69.10	68.47 ± 71.76	0.169
ALT (IU/L)	75.34 ± 118.98	50.77 ± 37.14	0.531	62.21 ± 77.61	74.23 ± 98.27	0.474
Sex, n (%)			0.016			0.08
Female	17 (22.08)	3 (5.36)		9 (25.71)	1 (4.35)
Male	60 (77.92)	53 (94.64)		26 (74.29)	22 (95.65)
Drinking, n (%)			0.173			1
No	54 (70.13)	32 (57.14)		24 (68.57)	15 (65.22)
Yes	23 (29.87)	24 (42.86)		11 (31.43)	8 (34.78)

BMI: Body mass index; HBsAg: Hepatitis B surface antigen; AFP: Alpha-fetoprotein; ALB: Albumin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.